Advertisement

Related Videos

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Cost of Care
Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Advertisement

Advertisement




Aug
10
Today In Oncology
Kinase Inhibitor Approved for Nonsquamous NSCLC With HER2 TKD–Activating Mutations
Potential New Second-Line Standard of Care Emerges in Small Cell Lung Cancer
Mortality in Advanced-Stage Ovarian Cancer—Effect of Neoadjuvant Chemotherapy and Cytoreductive Surgery Case Volume
Smoking Cessation in Cancer Care: Challenges and Opportunities
GLP-1 Receptor Agonists vs Other Glucose-Lowering Drugs: Survival in Older Patients With Cancer and Diabetes
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo